M&A activity vigorous in CDMO arena: CPhI outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.
Ascendia Pharmaceuticals Secures Growth Equity Investment from Signet Healthcare Partners
News provided by
Share this article
Share this article
NORTH BRUNSWICK, N.J., April 8, 2021 /PRNewswire/ Based in North Brunswick, NJ, Ascendia Pharmaceuticals, Inc. ( Ascendia ) is a specialty contract development and manufacturing organization (CDMO) dedicated to developing and manufacturing enhanced formulations for pre-clinical, clinical stage drug candidates, and marketed drug products. The investment was made by Signet Healthcare Partners ( Signet ), a New York-based growth equity firm specializing in healthcare investments. The proceeds will be used to fund Ascendia s facility expansion to support the growing demand in the sector.
Founded in 2012, Ascendia offers a comprehensive suite of pre-formulation, formulation development, manufacturing, and stability services for parental, oral, and topical dosage forms. The Company also provides analytical method development and validation